





# PHARMACEUTICAL 2019

## Biohaven Pharmaceutical Holding Co Ltd. Rank 276 of 371



The relative strengths and weaknesses of Biohaven Pharmaceutical Holding Co Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biohaven Pharmaceutical Holding Co Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Biohaven Pharmaceutical Holding Co Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 202% points.

The company's Economic Capital Ratio, given in the ranking table, is -379%, being 47% points below the market average of -331%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 272,339           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 19,534            |
| Liabilities, Non-Current                    | 2,043             |
| Other Assets                                | 11,425            |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 467               |
| Other Liabilities                           | 117,515           |
| Other Net Income                            | -15,901           |
| Property and Equipment                      | 6,248             |
| Research and Development                    | 189,951           |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 34,603            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 290,012           |
| Liabilities              | 139,092           |
| Expenses                 | 225,021           |
| Stockholders Equity      | 150,920           |
| Net Income               | -240,922          |
| Comprehensive Net Income | -240,922          |
| Economic Capital Ratio   | -379%             |

